Literature DB >> 29740676

Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.

Jullye Campos Mendes1, Palmira de Fátima Bonolo2, Maria das Graças Braga Ceccato3, Juliana de Oliveira Costa2, Adriano Max Moreira Reis3, Henrique Dos Santos4, Micheline Rosa Silveira3.   

Abstract

OBJECTIVE: To evaluate the prevalence of adverse drug reactions (ADR) and associated factors during the use of Highly Active Antiretroviral Therapy (HAART) in patients initiating treatment.
METHODS: This is a cross-sectional analysis of a prospective study conducted in three public referral services specialized in HIV/AIDS care in Belo Horizonte, Brazil. Self-reported ADR and explanatory variables were obtained from face-to-face interview and from Information Systems. Associated factors with ADR were evaluated by logistic regression in SPSS software v.22.
RESULTS: We included 399 patients, of which 85.5% reported at least one and 72.7% up to 5 ADRs after HAART initiation. Neurological reactions were the most frequent, with self-reported ADRs being distinct according to HAART regimen used. The global model showed higher chance of ADRs among females (OR = 3.52) and illicit drug users (OR = 2.28). Lower chance of ADRs was found for patients aged > 33 years (OR = 0.37), DTG/TDF/3TC users (OR = 0.41), and higher physical domain of quality of life (OR = 0.78). The model restricted to patients using the single-tablet regimen EFV/TDF/3TC showed lower ADRs among patients with CD4+ T lymphocyte count > 200 cells/mm3 (OR = 0.23) and higher independence domain of quality of life (OR = 0.74). The model restricted to DTG/TDF/3TC and to other regimens showed lower ADRs with higher physical domain of quality of life (OR = 0.74 and OR = 0.55, respectively).
CONCLUSIONS: The prevalence of self-reported ADRs to first-line antiretroviral regimens was high and patients using DTG/TDF/3TC had a smaller number of ADRs. In addition to HAART regimen, sociodemographic, clinical, and quality of life characteristics were associated with ADRs.

Entities:  

Keywords:  Antiretroviral therapy; Dolutegravir; Drug-related side effects and adverse reactions; HIV; Highly active; Single-tablet regimen

Mesh:

Substances:

Year:  2018        PMID: 29740676     DOI: 10.1007/s00228-018-2472-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   3.064


  41 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 2.  How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.

Authors:  Emilie Elliot; Mimie Chirwa; Marta Boffito
Journal:  Curr Opin Infect Dis       Date:  2017-02       Impact factor: 4.915

3.  Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil.

Authors:  Palmira de F Bonolo; Cibele C César; Francisco A Acúrcio; Maria das Graças B Ceccato; Cristiane A Menezes de Pádua; Juliana Alvares; Lorenza N Campos; Ricardo A Carmo; Mark D C Guimarães
Journal:  AIDS       Date:  2005-10       Impact factor: 4.177

4.  Preliminary development of the World Health Organsiation's Quality of Life HIV instrument (WHOQOL-HIV): analysis of the pilot version.

Authors:  K O'Connell; S Skevington; S Saxena
Journal:  Soc Sci Med       Date:  2003-10       Impact factor: 4.634

5.  Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.

Authors:  Paola Cicconi; A Cozzi-Lepri; A Castagna; E M Trecarichi; A Antinori; F Gatti; G Cassola; L Sighinolfi; P Castelli; A d'Arminio Monforte
Journal:  HIV Med       Date:  2009-09-01       Impact factor: 3.180

6.  Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.

Authors:  Megan E O'Brien; Rebecca A Clark; C Lynn Besch; Leann Myers; Patricia Kissinger
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-01       Impact factor: 3.731

7.  Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.

Authors:  George I Eluwa; Titilope Badru; Kenneth A Agu; Kesiena J Akpoigbe; Otto Chabikuli; Christoph Hamelmann
Journal:  BMC Clin Pharmacol       Date:  2012-02-27

8.  Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.

Authors:  Nicolas Despiégel; Delphine Anger; Monique Martin; Neerav Monga; Qu Cui; Angela Rocchi; Sonia Pulgar; Kim Gilchrist; Rodrigo Refoios Camejo
Journal:  Infect Dis Ther       Date:  2015-06-23

9.  Potential drug interactions in patients given antiretroviral therapy.

Authors:  Wendel Mombaque Dos Santos; Silvia Regina Secoli; Stela Maris de Mello Padoin
Journal:  Rev Lat Am Enfermagem       Date:  2016-11-21

10.  Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study.

Authors:  Henry Namme Luma; Marie-Solange Doualla; Simeon-Pierre Choukem; Elvis Temfack; Gloria Ashuntantang; Henry Achu Joko; Sinata Koulla-Shiro
Journal:  Pan Afr Med J       Date:  2012-07-27
View more
  4 in total

Review 1.  HIV and Substance Use in Latin America: A Scoping Review.

Authors:  Hanalise V Huff; Paloma M Carcamo; Monica M Diaz; Jamie L Conklin; Justina Salvatierra; Rocio Aponte; Patricia J Garcia
Journal:  Int J Environ Res Public Health       Date:  2022-06-12       Impact factor: 4.614

2.  Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.

Authors:  Noelia Fernández-Bargiela; Sandra Rotea-Salvo; Luis Margusino-Framiñán; Vanesa Balboa-Barreiro; Isabel Martín-Herranz; Ángeles Castro-Iglesias; Álvaro Mena-De-Cea; Soledad López-Calvo; Pilar Vázquez-Rodríguez; Enrique Míguez-Rey; Purificación Cid-Silva
Journal:  Eur J Hosp Pharm       Date:  2020-10-13

3.  Health-Related Quality of Life and Coping Strategies in a Cohort Study of Highly Active Antiretroviral Therapy Naïve Patients Adherence.

Authors:  Patricia de Oliveira França; Lorena Rocha Ayres; Lúcia Helena Pimassoni; Crispim Cerutti Junior
Journal:  Int J Clin Pract       Date:  2022-02-09       Impact factor: 3.149

4.  Efficacy and safety of traditional Chinese herbal medicine combined with HAART in the treatment of HIV/AIDS: A protocol for systematic review and meta-analysis.

Authors:  Zhenzhen Qian; Yujin Zhang; Xiaoli Xie; Junwen Wang
Journal:  Medicine (Baltimore)       Date:  2021-12-30       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.